Recce Pharmaceuticals has obtained key patent protection in China, expanding intellectual property coverage for its antimicrobial drug development platform.

Taho Pharmaceuticals' TAH3311, an apixaban oral dissolving film (ODF), demonstrated bioequivalence to Eliquis® tablets in a pivotal study.

INmune Bio's XPro™ demonstrated the ability to promote remyelination in animal models of demyelinating diseases, according to a publication in *Cell Reports*.

Acelyrin's lead drug candidate, Izokibep, is currently in Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and Phase 2 trials for Axial Spondyloarthritis.

Arrowhead Pharmaceuticals has submitted a new drug application to the FDA for plozasiran for the treatment of familial chylomicronemia syndrome (FCS).

Glenmark Pharmaceuticals has initiated a recall of approximately 1.5 million bottles of an ADHD medication from the US market following FDA oversight.

Rocket Pharmaceuticals' RP-A501 gene therapy demonstrated significant efficacy in Phase 1 trial for Danon Disease, achieving 50% above-normal LAMP2B protein expression in treated patients.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland in Dublin.

Lundbeck will acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, a promising drug for developmental and epileptic encephalopathies (DEEs).

The MHRA has approved sugemalimab (Eqjubi) as a first-line combination treatment for metastatic non-small cell lung cancer (NSCLC) in adults.

Kintor Pharmaceuticals has reached a significant milestone in their Phase III clinical trial evaluating a novel treatment for androgenetic alopecia. The development represents a potential breakthrough in addressing a condition affecting millions globally, with the trial progressing according to schedule.

Ironwood Pharmaceuticals has announced that a confirmatory Phase 3 trial will be required for apraglutide in short bowel syndrome with intestinal failure, following its $1 billion acquisition of VectivBio.

Ketamir-2 demonstrated superior efficacy compared to Gabapentin and Pregabalin in preclinical studies for chemotherapy-induced neuropathic pain.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome, a rare genetic disease with no approved treatments.

The FDA has granted accelerated approval to Ziihera (zanidatamab) for adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC).

Recce Pharmaceuticals has received approval from Indonesia's Badan POM to begin a Phase 3 trial of RECCE 327 topical gel for diabetic foot infections.

Alnylam forecasts 2025 net product revenues between $2.05 billion and $2.25 billion, a 31% increase from 2024, driven by its TTR and rare disease franchises.

Chinese pharmaceutical giant Jiangsu Hengrui plans to raise up to $1.27 billion in its Hong Kong IPO, making it one of the city's largest offerings this year.

Actinium Pharmaceuticals aligned with the FDA on a Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory AML, aiming for optimized dosing and reduced trial timelines.

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children's Health Ireland, marking the first evaluation in a pediatric patient.